Clinical Trial

Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-center, open-label, sequential drug interaction study The primary objectives are: To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-01.
Status change: Not Yet Recruiting → Completed 2026-03-12
Trial Details
NCT Number NCT07049107
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Health Volunteer
Enrollment 14 participants
Start Date 2025-06-23
Primary Completion 2025-07-21 (estimated)
Study Completion 2025-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-16